UniProtKB/Swiss-Prot Q9Y5C1: Variant p.Lys63Thr

Angiopoietin-related protein 3
Gene: ANGPTL3
Feedback?

Variant information Variant position:

63 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Lysine (K) to Threonine (T) at position 63 (K63T, p.Lys63Thr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from large size and basic (K) to medium size and polar (T) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

-1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

Associated with low plasma triglyceride level; fails to suppress LPL activity in vitro. Any additional useful information about the variant.
Other resources:

Links to websites of interest for the variant.

Variant rs146749211 [ dbSNP | Ensembl ]

Sequence information Variant position:

63 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

460 The length of the canonical sequence.
Location on the sequence:

VKILANGLLQLGHGLKDFVH K TKGQINDIFQKLNIFDQSFY The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         VKILANGLLQLGHGLKDFVHKTKGQINDIFQKLNIFDQSFY

Mouse                         VKILANGLLQLGHGLKDFVHKTKGQINDIFQKLNIFDQSFY

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	17 – 460	Angiopoietin-related protein 3
Chain	17 – 224	ANGPTL3(17-224)
Chain	17 – 221	ANGPTL3(17-221)
Region	17 – 207	Sufficient to inhibit LIPG/EL phospholipase activity
Region	17 – 165	Sufficient to inhibit LPL lipase activity
Mutagenesis	62 – 63	HK -> IN. Abolishes effect on plasma triglyceride level; when associated with N-65.
Mutagenesis	63 – 63	K -> N. Abolishes inhibitory effect on LIPG/EL phospholipase activity; when associated with N-65.
Mutagenesis	65 – 65	K -> N. Abolishes effect on plasma triglyceride level; when associated with 62-I-N-63.
Mutagenesis	65 – 65	K -> N. Abolishes inhibitory effect on LIPG/EL phospholipase activity; when associated with N-63.

Literature citations
Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans.
Romeo S.; Yin W.; Kozlitina J.; Pennacchio L.A.; Boerwinkle E.; Hobbs H.H.; Cohen J.C.;
J. Clin. Invest. 119:70-79(2009)
Cited for: VARIANTS THR-63; GLY-91; PHE-164; SER-173; THR-259; GLN-288; PRO-292; LYS-375 AND CYS-417; CHARACTERIZATION OF VARIANTS THR-63; GLY-91; PHE-164; SER-173; THR-259; ARG-GLN; PRO-292; LYS-375 AND CYS-417;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.